Notice is hereby given that, on January 16, 2009, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”) Industrial Macromolecular Crystallography Association (“IMCA”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, SmithKline Beecham Corporation, operating as Glaxo SmithKline, Philadelphia, PA; and Pfizer Global Research and Development, Groton, CT have withdrawn as parties to this venture.
No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and IMCA intends to file additional written notifications disclosing all changes in membership.
On October 23, 1990, IMCA filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on December 3, 1990 (55 FR 49952).
The last notification was filed with the Department on August 21, 2007. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on November 7, 2007 (72 FR 62865).Start Signature
Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. E9-4018 Filed 2-25-09; 8:45 am]
BILLING CODE 4410-11-M